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Home extended hours hemodialysis improves some
measurable biological and quality-of-life parameters over
conventional renal replacement therapies in patients with
end-stage renal disease. Published small studies evaluating
costs have shown savings in terms of ongoing operating
costs with this modality. However, all estimates need to
include the total costs, including infrastructure, patient
training, and maintenance; patient attrition by death,
transplantation, technique failure; and the necessity of
in-center dialysis. We describe a comprehensive funding
model for a large centrally administered but locally delivered
home hemodialysis program in British Columbia, Canada that
covered 122 patients, of which 113 were still in the program
at study end. The majority of patients performed home
nocturnal hemodialysis in this 2-year retrospective study.
All training periods, both in-center and in-home dialysis,
medications, hospitalizations, and deaths were captured
using our provincial renal database and vital statistics.
Comparative data from the provincial database and
pricing models were used for costing purposes. The total
comprehensive costs per patient—incorporating startup,
home, and in-center dialysis; medications; home remodeling;
and consumables—was $59,179 for years 2004–2005 and
$48,648 for 2005–2006. The home dialysis patients required
multiple in-center dialysis runs, significantly contributing to
the overall costs. Our study describes a valid, comprehensive
funding model delineating reliable cost estimates of starting
and maintaining a large home-based hemodialysis program.
Consideration of hidden costs is important for administrators
and planners to take into account when designing budgets
for home hemodialysis.
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Home nocturnal (nightly) hemodialysis (HD) improves key
measurable biological and quality-of life-parameters in end-
stage renal disease patients over conventional renal replace-
ment modalities.1–6 Published studies evaluating the costs of
this modality have shown savings in terms of ongoing
operating costs.7–9 These studies were performed in single
centers with small number of patients and were not intended
to capture the total costs of a program, including the sunk
capital costs tied to infrastructure, patient training, and
maintenance over time. Furthermore, data are lacking that
describe the economic outcomes over time due to patient
attrition from the program for various reasons (death,
transplantation, and technique failure) and the costs tied to
home HD (HHD) patients needing in-facility runs.
The key outcomes for our HHD program in British
Columbia, Canada, described at 2 years have been previously
published,10 and focus on parameters that significantly effect
the costs of delivering this modality of renal replacement
therapy; specifically, we report survival on this technique and
reasons for leaving the program, hospitalizations, and number
of facility-based runs required per patient. The majority of these
HHD patients were performing (nightly) nocturnal treatments.
The purpose of this manuscript is to describe a
comprehensive funding model for a large centrally adminis-
tered, but locally delivered, HHD program in British
Columbia, Canada. This report will describe a validated
activity-based costing model for a large HHD program with
reported programmatic outcomes, including the up-front
sunk capital costs, costs attributable to patient attrition from
the program, and basic complications. This will allow for a
better estimate of overall budgetary and program effects on
centers wishing to start a new HHD program.
RESULTS
We report the experience with 2 fiscal years of the provincial
HHD program, representing 24 months of data from April
2004 until March 2006.
Baseline program demographics
The HHD program in the province of British Columbia
began in April 2004. In the first fiscal year, 53 patients were
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2010 International Society of Nephrology
Received 16 February 2009; revised 27 November 2009; accepted 29
December 2009; published online 10 March 2010
Correspondence: Paul Komenda, Department of Medicine, University of
Manitoba, St Bonifcace General Hospital, 409 Tache Avenue, BG007,
Winnipeg, Manitoba, Canada R2H 3A6. E-mail: paulkomenda@yahoo.com
Kidney International (2010) 77, 1039–1045 1039
enrolled and trained. As of March 2006 (the end of the
second fiscal year of the program), the province had 113
patients performing HHD. Of these patients, 70% performed
(nightly) nocturnal HD (4–7 days a week over 6 h a
treatment), 19% performed short daily HD (up to 7 days a
week less than 4 h per day) treatments, and 10.5%
performed conventional HD (thrice weekly 4 h) at home.
Baseline demographics of our HHD patients when
compared with the average provincial community HD
patient are presented in Table 1. HHD patients were on
average younger than community HD patients (52.3 vs 62.8
years old, Po0.001), had slightly less diabetes (16.9 vs 19%,
Po0.001), and were less likely to have cardiovascular
morbidity (49.3 vs 53.7%, Po0.001). The ethnic diversity
of our HHD program was representative of our HD
population as a whole. These demographic variables
represent the cohort of patients who were still on the HHD
program as of April 2006. We have previously reported that
this cohort of patients did not have any statistically
significant demographic variables or comorbid conditions
than those who suffered early technique failure or required
in-center runs in univariate or multivariable analyses.10
Startup costs
All prospective costing data are represented in Table 2 from
the perspective of the health-care payer. Table 2 provides
aggregate costs for the setting up of a new HHD program
with the more granular costing components provided in
subsequent tables. Startup costs for the first year of our
program totaled $510,000, including training the first cohort
of 53 patients, costs of educating and recruiting nurses, and
clerical support. Each patient started on HHD costs of
$11,665 to train on average. This is a blended average from
the payer’s perspective depending on probabilities that
patients will require a given length of training. An estimate
of program startup costs for 2004–2005 is $18,830 per patient
and startup costs for patients who started in 2005–2006 is
$17,306 per patient. This relative decrease in the second year
is because of the reduced shared fixed costs of program
startup tied to administrative activities.
Staffing costs
Staffing costs are reported under ‘training costs’ from a total
program perspective per year in Table 2. From a payer’s
perspective, it costs $804,865 to train 69 patients in the
2005–2006 fiscal period; however nine patients left the
program in this same year. As salaries vary from year to
year and between centers, Table 3 provides a breakdown of
the full-time equivalents spent per professional with each
patient in training a new patient in the first year and the
Table 1 | Demographics of HHD patients versus the average community and in-center HD patient in British Columbia (June
2006)
Variable HHD patients Community HD patients In-center HD patients
Sex (female) 25% 35.2% 42.6%
Age 52.3±13.6 62.8±15.7 66.7±15.2
Diabetes 19.8% 32.9% 43.2%
Diagnosed CVD 49.3% 53.7% 57.5%
Race
Caucasian 68.7% 71.1% 55.1%
Asian (Oriental) 13.4% 9.6% 25.9%
Asian (Southeast) 6.0% 13.1% 12.7%
First Nations 9.0% 5.0% 4.6%
Other 3.0% 1.1% 1.8%
Abbreviations: CVD, cardiovascular disease; HD, hemodialysis; HHD, home hemodialysis.
Table 2 | Total startup, training, and maintenance cost
components (excluding costs of dialysis runs) from the
BCPRA perspective of home hemodialysis program
Fiscal year 2004–2005 2005–2006
No. of entry patients (total–exits) 53 69 (122–9 = 113)
No. of exits 0 9
New entry patient training costs NA $804,865
Startup costsa $510,000 $20,000
Home renovations $150,000 $107,500
Equipment warranty $36,000 $443,000
HHD/RO machine costsb N=53 $185,500 N=60 $395,500
Hospitalizationc (PYs/costs) 0.36 $116,500 0.77 $282,500
Total $998,000 $2,053,365
Total cost/PT $18,830 $17,306
Abbreviations: BCPRA, British Columbia Provincial Renal Agency; HHD, home
hemodialysis; NA, not available; PT, patient; PY, patient years; RO, reverse osmosis.
aStartup costs in the first year include training and recruitment of clinical and
administrative staff, setting up protocols, and so on. These startup costs also include
training of the first patients, which in subsequent years is calculated under ‘new
entry patient training costs’.
In the program’s first year, we rolled training costs of patients into the ‘admin’ costs
of setting up the program as these activities occurred simultaneously for the most
part. We felt it more appropriate to account for ‘training’ costs separately in the
second year as this became a variable cost (that is, dependent on the number of
patients trained), whereas some fixed costs still occurred in the second year
(pertaining to admin costs of setting up additional training sites, and so on). Because
more patients were trained in the second year, this accounted for greater costs
attributable to ‘training costs’. These marginal costs may have been higher on a per
patient basis, due to loss of economies of scale with additional training sites being
set up, not yet running at full capacity.
bHHD machines and RO water purifiers were costed at 35,000 dollars each and
amortized in a straight-line manner over a 10-year period as per biomedical
engineering staff recommendations.
cAll hospitalization days for HDD patients while on the program were tracked
provincially. They are reported in terms of patient years spent in hospital.
Microcosting techniques per admission day were not possible, and hence an
average cost of $1165 per patient day in hospital was assumed as per published
estimates for a Canadian Hemodialysis patient admitted day.12
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average time spent with each patient in subsequent ‘main-
tenance’ years.
Maintenance dialysis costs
At the end of the 2005–2006 fiscal year, it costed 1.95 million
dollars to deliver 65.58 patient years of HHD to 113 patients.
This dollar figure incorporates the costs of patients who were
trained, but did not continue HHD. These 113 patients
required, in addition, a total of 17.52 patient years worth of
facility HD runs for various reasons (hospital admission,
respite, and so on), adding an additional 655,661 dollars of
cost to maintaining these patients on the HHD program.
Table 4 depicts the costs for patients maintained on HHD
after training and includes the costs for in-facility runs. These
were only added after the patient had been trained and was
performing independent dialysis at home. Maintenance
dialysis costs were $40,349 per patient in 2004–2005 and
$31,342 per patient in 2005–2006.
Patient flow
Of the 122 patients trained from April 2004 until April 2006
in our HHD program, 113 were still on the program as of
April 2006. Seven patients did not complete training for
various reasons and nine left the program. The most
common reasons for exit from the program were transplan-
tation and death, published separately.10
Total costs
The total comprehensive cost for an HHD patient, incorpor-
ating startup costs, maintenance dialysis costs, medications,
and consumables was $59,179 for 2004–2005 and $ 48,648 for
2005–2006.
DISCUSSION
This represents the first published report of a validated
funding model, helping to delineate true costs associated with
the starting and maintaining of a province-wide HHD
program in what is now one of the largest HHD programs
in Canada.
In our study, total comprehensive costs for an HHD
patient, incorporating startup costs, maintenance dialysis
costs, medications, and consumables is $59,179 for 2004–
2005 and $48,648 for 2005–2006. This is consistent with
costing studies previously reported;7–9 however, it incorpo-
rates, aside from inflationary increases, considerably more
components in the funding model, such as in-center HD,
home renovations, and hospitalization costs. Per patient costs
are lower in the second year and this is likely because of
several factors. First, the up-front fixed administrative costs
tied to beginning a program (setting up of protocols,
meetings, travel, and so on) are less in the second year.
Second, as more patients are added to the program, the
relative costs of training new patients are shared among more
prevalent patients already on treatment; thus, as programs
grow in size, the effect of training new patients on operating
the program have less of an affect. These declining per patient
costs may be underestimated in our study as we were still in
the process of setting up new training sites in the second year
and full efficiencies may not yet have been realized.
Our report is unique to the literature in documenting the
outcomes and funding required for the starting and
maintenance of an HHD program in several ways. First,
many other studies have focused on the savings of operating
costs, and ignored the significance of training and recruiting
administrative and clinical staff, producing protocols,
performing home renovations, and purchasing and main-
taining HHD machines and water purifiers. We have
included all of these sunk costs, which are required and
important from a payer’s perspective to accurately project
costs in initiating a large-scale program.
Second, because this report documents the actual course
of a patient and changes in health status over time, it gives a
more realistic idea of how many patients are lost in a
Table 3 | Staffing costs (breakdown of FTEs spent by each member of team to train and maintain one home hemodialysis
patient per year)
First year (training/maintenance) Subsequent years (maintenance)
Staff category Direct hours Paid FTEs Direct hours Paid FTEs
Clerk 0.5 0.0005 6.0 0.0059
Dietician 2.0 0.0020 7.2 0.0071
Pharmacist 0.5 0.0008 4.3 0.0068
Nurse 161.6 0.1699 11.8 0.0124
Social work 4.0 0.0035 5.7 0.0049
HD technician 25.5 0.0268 24.6 0.0259
Abbreviations: FTE, full-time equivalent; HD, hemodialysis.
Table 4 | Dialysis costs for patients in home program from
payer perspective (excluding training)
2004–2005 2005–2006
Patient years Cost Patient years Cost
HHD maintenance costsa 12.36 513,769 65.58 1,948,816
Inpatient runsb 9.51 368,656 17.52 655,661
Total 21.87 882,425 83.1 2,604,477
Cost/patient year $40,349 $31,342
Abbreviation: HHD, home hemodialysis.
aIncludes consumables, plus supporting staff costs per patient (from Table 3).
bBased on British Columbia Provincial Renal Agency funding model ‘per patient
run’.11
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program to death, technique failure, and modality change.
The invested cost in an individual patient is significant in the
first year in terms of training, home renovations, and
machine purchase. Losing a patient, especially early on,
affects significantly the per patient cost of the entire program.
Our experience over 3 years is that approximately 6–8% of
our patients per year exit the program and we have accounted
for these added costs. The costs of exiting and returning to
different renal replacement modalities and transplantation
versus death are different. For the sake of simplicity, we have
not made that distinction in this study. It should be noted
that the percentage of patients exiting may change as the
program increases in size or if selection criteria are changed.
However, a minimum of 6–8% ‘failure’ from any cause
should be acknowledged in any program and built into
prospective funding models.
Third, this is the first study we are aware of to document
the continued need for patients on HHD to receive a certain
number of in-facility runs for a variety of reasons. A
significant number of runs can be attributed to patients with
access problems, requiring procedures, needing respite, or
other illnesses. This is important in terms of adding a cost
burden to deliver dialysis care to these patients, and is also
important to administrators and program planners in
gauging the in-center capacity that needs to be maintained
to service the home patients.
Last, we had limited selection bias for our patients due to
comorbidity or demographic variables. All patients were
considered for HHD according to very liberal criteria. We
considered any patient a candidate for HHD who can speak
English, can reliably be taught the technique, and who is
expected to survive for longer than 1 year. We are not
constrained by our provider to pay for this type of treatment,
which is common in other Canadian centers. Patients likely
to choose this modality are self-selected as being more highly
motivated, independent individuals. This may explain the
differences in the reported baseline demographic character-
istics when our home patients are compared with the average
community hemodialysis patient.
In addition to the reported physiologic and quality-of-life
benefits with nocturnal (nightly) HHD, potential economic
benefits have been published. Three Canadian centers have
reported substantial cost savings with their HHD programs
versus in-center hemodialysis on a pilot basis. Cost savings
for nocturnal (nightly) HHD programs in these studies
ranged anywhere from approximately 24,000 to 63,000 USD
per patient per year depending on the costing frameworks
used mainly attributable to reductions in staffing and
overhead.
We have previously published some patient outcomes for
this similar cohort.10 Mean biochemical and clinical para-
meters were all within provincial and national target ranges at
baseline and at the time of study follow-up cessation. Overall,
34 individual patients required hospital admission and 95%
of the cohort required at least one in-center run after training
was completed (0.5 hospital admissions and 11 in-center run
per patient year of HHD delivered). The 1- and 2-year
technique survival was 81 and 61%, respectively, which was
85 and 74% when censored for transplantation. We
were unable to show any significant predictors of technique
survival using demographic, biochemical, or other
variables.
Although savings have been shown in terms of main-
tenance costs in some of the original costing studies with
HHD,7–9 major barriers still exist in convincing payers to
assume the large capital costs in starting such programs.
These previous studies, although well executed in terms of
reporting itemized costing data, were not designed to capture
all of the true costs tied to both starting and maintaining an
HHD program. First, startup costs in terms of patient
training, infrastructure, home renovations, and machines
were censored from the costs reported in these studies. In
addition, patients lost to programs because of transplanta-
tion, death, or technique failure adds a significant cost to the
overall program, especially in the early stages as sunk costs
tied to an individual patient in the first year exceeds the costs
if that patient had stayed in facility-based dialysis.
The British Columbia Provincial Renal Agency (BCPRA)
has a comprehensive funding model for nephrology patients
in the province. In this study we report our experience, on a
provincial basis, on the costs of starting and maintaining the
largest HHD cohort in Canada from the perspective of the
payer, in this case the Ministry of Health.
This funding model approximates the true costs of
running a program as we also included here the costs tied
to training and losing patients to attrition from the program
for various reasons and built that into our per unit cost. In
addition, where previous studies in this area have primarily
focused on a pre-selected population to calculate costs, we
report our experience with a non-selected population over
time with complete data capture of all runs over the period
studied. This model will hopefully aid administrators and
nephrologists who are contemplating the implementation of
home programs. We provide here the components required
to make a business case for the establishment, maintenance,
and expansion of HHD programs.
Our report clearly has limitations. First, this is not a
randomized control trial. In this study we report simply the
costs of starting and maintaining a program, whereas other
studies8,9 have attempted to compare operating costs of their
HHD programs to demographically matched cohorts of in-
center patients. There are some methodological concerns
with this approach, namely all costs are not captured because
costs tied to patient attrition and in-facility runs were not
accounted for. In addition, even matching baseline demo-
graphics between groups does not take into account
significant confounders such as patient motivation, which
self-selects for a unique group who will volunteer for this
modality. The costs of running a conventional hemodialysis
program are generally well known in most large centers. We
felt it more important to report the components of a
comprehensive funding model from a payer’s perspective,
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than to try to do direct comparisons with a non-randomized
cohort of matched patients. Randomized trials are currently
underway that will hopefully address the question of direct
cost comparisons with conventional hemodialysis with less
inherent biases.
There are other important factors to keep in mind that
our study did not take into account. Many of the areas in
which patients are performing HHD are remote communities
without access to in-center units. Even in urban centers, with
most units operating at 100% capacity in the province, it
would be a tremendous capital expense to accommodate all
of these patients with facility-based HD. Many new HD units
would have to be constructed in several centers. In many
cases, patients and their families would be forced to relocate
close to centers offering hemodialysis if not for this modality
at great expense and emotional hardship. In addition, many
of our patients who have been on the nocturnal program are
now able to return to gainful employment in some capacity
and our study did not capture these indirect costs from a
societal standpoint. Randomized trials are ongoing at present
to help better delineate these costs.
An admitted weakness of this study is that we have no idea
how far we can amortize ‘startup’ costs over a patient’s time
on HHD. As more long-term data on patient technique
survival are published within registries, we will be better
poised to use Markov modeling techniques in handling these
costs. We have made an assumption and chosen to amortize
our technological costs (of the machine) over an 8-year
period as extrapolated from our experience with the in-center
dialysis machines we use. This may be an underestimate as
home machines are used less intensely than in-center
machines.
It should be mentioned that this report was not designed
to capture all the granular detail in how much each
component in the funding model costs. We did not use
microcosting techniques in terms of medications, erythro-
poietin costs, and individual patient training costs. We have
not found that our erythropoietin costs have been reduced in
patients receiving nocturnal (nightly) HHD. This has been
confirmed by others, including the randomized control trial
by Culleton et al.1 and in a systematic review by Walsh et al.6
Although other medication costs may slightly differ, these are
not significant cost drivers in the overall model as confirmed
by other costing studies in this area.7,9
As our report is from the Ministry of Health/payer’s
perspective, these details are not specifically relevant. Our
funding model as it is has been indirectly validated over the
two first fiscal periods with no budget overruns. Therefore,
the numbers presented are most likely generalizable to other
paying agencies that are looking to start regional large-scale
programs. We are in the process of retrospectively validating
our funding assumptions with microcosting techniques. This
retrospective analysis of costs will allow us to provide
confidence intervals around our point estimates for costs, but
at present we are unable to do so. Our staffing estimates
currently do take into account differential times for training
and so on, based on the pilot data gathered in the first year of
the program.
Last, quality-of-life metrics were not a component of this
report. As mentioned, several studies now have confirmed
that patients receiving more frequent nocturnal (nightly)
HHD have significantly improved quality-of-life parameters
measured on several different validated scales, both disease
specific and general. McFarlane et al.10 are the only group to
our knowledge that have published a true cost utility analysis
adjusting accounting costs for the improved quality-of-life
scores found in facility-based HD versus nocturnal (nightly)
HHD. Their models found significantly magnified savings
when quality-adjusted life years were taken into account
($125,845/quality-adjusted life years for in-center HD vs
$71,443/quality-adjusted life years for nocturnal HD). These
findings will have to be confirmed in further randomized
studies using costing models including all costs associated
with running an HHD program such as ours.
MATERIALS AND METHODS
Funding data for the HHD program were collected for two
successive fiscal periods beginning in April 2004 and ending March
2006. Startup capital costs in addition to the first year maintenance
costs was included prospectively during this time. Costing models
are based on the Renal Resource Manual published by an external
consulting group contracted by the BCPRA in 2004.11 This model
was created using real-life data on staffing hours from the pilot
project,11 and was validated for accuracy before implementation by
a series multidisciplinary focus group including health-care workers
from different HHD sites (in various health authorities), adminis-
trators, and external consultants (see Figure 1). This funding model
has been implemented successfully in two successive fiscal periods
with no cost overruns. Further validation steps were performed by
the consulting group at regular intervals, which confirmed a high
degree of correlation11 between staffing levels and funding model
predictions.
Baseline demographic data
As of April 2006, cross-sectional, demographic data were collected
on all of the prevalent patients enrolled in the program. Data were
captured in terms of gender, age, number of patients with diabetes
mellitus, confirmed diagnosis of coronary artery disease, and
ethnicity. As this is a provincial program, data were also captured
on where each of the patients was living in the province.
Components of the funding model
Startup costs (considered for training and first year on
treatment). All of the sunk costs associated with starting an
HHD program were accounted for. This included funds to hire and
train both administrative staff in addition to the required full-time
equivalents for nurses and allied health professionals, including
dieticians, pharmacists, and social workers, according to best
practice guidelines as defined by the BCPRA multidisciplinary
committee. Because this was a large-scale, provincial program, costs
tied to executive steering personnel from both a clinical and
administrative standpoint were also built into this model.
Fixed one-time capital expenditures on an individual patient
basis are accounted for in terms of startup costs. We include costs
tied to patient home renovations (paid for by the BCPRA), the
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purchase of HHD machines, and reverse osmosis water purifiers.
The costs of the HHD machines and reverse osmosis water purifiers
were depreciated in a straight-line manner over 10 years, as
recommended by the biomedical engineering department at the
Vancouver General Hospital. Machines were accounted for as a
BCPRA-owned resource, and hence one machine was required for
each active prevalent patient on the program.
Patient training. Data gathered from a pilot HHD program
within British Columbia were used in constructing the funding
model for staffing in the patient training phase. These assumptions
included 1:1 training over a 4-week period for 90% of new patients,
with 5% requiring 5 weeks and 5% requiring 6 weeks. We assumed
time for three home visits by a biomedical technician (evaluation of
home environment, renovations, and first run set-up). Actual hours
of input for clerks, pharmacists, dieticians, and social workers were
derived in a similar manner from the pilot program. These
parameters were validated in consultation with Working Group
members individually and in small groups incorporated best
practice concepts where possible based on discipline-specific
experience. Actual hours for activities performed were then
transformed into full-time equivalents, adjusting for vacation and
benefits paid. Full-time equivalents were next priced within each
discipline according to mid-level salary rates in 2003–2004 within
British Columbia.
Patient flow. Patients were tracked from the beginning of their
HHD training and considered ‘on treatment’ once they began
dialysis in their homes. Exits from the program were tracked both
during training and on treatment during the study period. In-center
runs were defined as those runs within a dialysis facility once
treatments were begun at home.
Maintenance costs (considered for second year on treat-
ment). Staff: Maintenance costs for nurses, dieticians, social
workers, pharmacists, and biomedical technicians were calculated
per patient year on HHD. These staffing costs were derived in the
same manner as described above for startup costs.
Consumables: Costs of materials associated with hemodialysis,
including filters, needles, tubing, and dialysate, were included in the
model. These costs were estimated by actual costs incurred during
the 1-year pilot program leading up to the creation of the funding
model. This model assumes that 80% of patients perform nocturnal
(nightly) HHD, 20% do short daily HD, and 10% do conventional
thrice weekly HD. We excluded patient-borne costs of increased
Staffing costs per
activity
(entry, per year
on program, exit)
Identify task or
activity
Estimated
time for
task
Frequency
of task
Factor by probability
task will occur
Calculated
time (hours)
Social
worker Pharmacist Dietician NurseClerk
Multiply by median salary +
benefits, British Columbia,
2003–04
Identify staff
completing
activity
(nurse, pharmacy, etc)
FTEs required (including benefits)FTEs required (including benefits)
Figure 1 | Schematic depiction of deriving funding model for staffing costs.
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electricity and water bills, as these were negligible in terms of
magnitude to the costs of the program as a whole. Also included
were the funding provided for patient medications, erythropoietin
therapy, and nutritional supplements. These amounts were calcu-
lated based on mean medication costs per patient that the BCPRA
provides.
Warranty/maintenance: Service contract costs for the upkeep and
maintenance of the HHD machines are included. These are variable
costs tied directly to the number of home machines in service at any
given time throughout the province.
Program exit costs: Because this analysis includes prospective
data, we captured on-treatment costs. Included in the global budget
were costs attributed to patients who went through training and
home renovations, but were unable to continue on HD at home
because of various reasons and had to resume conventional HD.
Patients who ‘exited’ the program (defined as 43 months of
uninterrupted dialysis in-center) were ascribed staffing costs
attributable to switching a patient to another modality, receiving a
kidney transplant, or dying. These included time on behalf of
nursing, clerks, and biomedical technicians, using similar meth-
odologies described above. The costs ascribed to patients who were
trained and maintained on HHD foro1 year were added to the ‘per
patient year’ costs of the patients who remained on the program to
more accurately reflect ‘total program costs per patient year’.
In-center runs: All hemodialysis runs required in-center by
patients on HHD were captured. A per run cost was ascribed to each
of these according to the BC Renal Agency Funding Model11 and
added to the HHD program costs per patient year on treatment.
CONCLUSION
In summary, this report represents the first of its kind
reporting the true relevant costs and patient outcomes in
terms of survival on technique in starting what is now one of
the largest and fastest growing nocturnal HHD program in
North America. It is the only report in the literature, to our
knowledge, to report all the components required in funding
an HHD program in terms of startup, maintenance, costs due
to loss of patients from the program, and the cost of home
patients requiring in-center runs of dialysis. As patient
numbers increase in a program, lower maintenance costs
marginalize the effects of higher fixed startup costs. Thus,
programs, which are starting out, should plan to grow rapidly
to realize these savings sooner and take advantage of the
economies of scale.
More accurate microcosting techniques, including time
and motion analysis for training costs, will be necessary to
confirm these results in a prospective randomized manner,
such as that planned by the Frequent Hemodialysis Network
trial currently enrolling patients.
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